Healthy Skepticism Library item: 18860

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Wieseler B, McGauran N, Kaiser T
Finding studies on reboxetine: a tale of hide and seek
BMJ 2010 Nov 12; 341:
http://www.bmj.com/content/341/bmj.c4942.extract

Abstract:

The antidepressant reboxetine, a selective noradrenaline (norepinephrine) reuptake inhibitor, has been approved in several European countries (including the United Kingdom and Germany) since 1997. However, approval was declined in the United States in 2001. The German Institute for Quality and Efficiency in Health Care (IQWiG) report on the benefit and harm of newer antidepressants concluded in 2009 that, overall, reboxetine was both ineffective and potentially harmful.